Back at Wilson Aarhus: From Pilot Data to World-First Newborn Screening Program

Key Proteo Co-Founder and CEO Dr. Sihoun Hahn, MD, PhD, presented at the Wilson Aarhus 2026 Symposium — widely regarded as the world's leading scientific conference dedicated to Wilson Disease. His presentation updated the global research community on an evidence base that has grown substantially since his last appearance at the symposium in 2024.

At Wilson Aarhus 2024, Dr. Hahn presented a 22,000-sample pilot study showing Key Proteo's Immuno-SRM platform could detect ATP7B peptide targets from standard dried blood spot specimens with high sensitivity, specificity, and no true false negatives.

At this year's symposium, Dr. Hahn shared the milestone that Washington State has officially added Wilson Disease to its newborn screening panel, making it the first program of its kind in the world. He also presented new data from a confirmed Wilson Disease patient cohort, in which peptide measurement confirmed ATP7B defects in majority of cases — the largest molecular validation of its kind to date. Dr. Hahn also presented encouraging early screening data from high-prevalence European populations in Sardinia and Gran Canary Island — where Wilson Disease affects as many as 1 in 2,000 individuals — including a validated AUC of 0.94 in the Gran Canary Island cohort, with Sardinian data ongoing due to limited sample size.

Key Proteo is grateful to the Wilson Aarhus Symposium for the platform to share this work with the global Wilson Disease community.